376 related articles for article (PubMed ID: 19770695)
1. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
2. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
4. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
5. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
6. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
7. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
9. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
11. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
12. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
13. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
14. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
Ferns RB; Kirk S; Bennett J; Cook PM; Williams I; Edwards S; Pillay D
AIDS; 2009 Oct; 23(16):2159-64. PubMed ID: 19571721
[TBL] [Abstract][Full Text] [Related]
15. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
16. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
[TBL] [Abstract][Full Text] [Related]
18. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
[TBL] [Abstract][Full Text] [Related]
19. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
20. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Delaugerre C
Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
